In recent years, the CAR-T industry has experienced a remarkable surge in funding. At first, the trend was subtle, but the tide has swelled as CAR-T therapies have reached the marketplace and created a funding boom. Today, CAR-T start-ups are being richly funded by investors and large pharma who are eager to get into this trending area of regenerative medicine.
Worldwide, more than 170 companies are now developing CAR-T products and therapies, with a total of 1,944 early and late-stage therapies in development. These companies have also entered into 110 collaboration agreements aimed at advancing various CAR-T candidates. Of these, only 38 have disclosed the value of their deals, which amounts to $23.58 billion. If we estimate the value of the undisclosed deals, the total value of these 110 collaborations is likely to reach approximately $67.9 billion.
The clinical successes of CAR-T therapies have sparked significant interest from venture capitalists globally. This increased activity has fueled advancements in CAR-T technology and the development of applications for both hematological cancers and other types of cancer. Since 2014, a total of 89 CAR-T companies have secured $7.7 billion in venture capital, enabling them to strengthen their foundations. Venture capital funding has remained strong and consistent throughout the development of the CAR-T industry.
Data shows that Initial Public Offerings (IPOs) within the CAR-T space were relatively slow last year. In 2024, only Kyverna Therapeutics went public, raising $319 million to support its anti-CD19 CAR-T therapies. However, from 2014 to present, 42 CAR-T companies have gone public, collectively raising $6.4 billion to further enhance their technology platforms, clinical trials, and corporate strategies.
Within this rapidly evolving industry, there are currently 72,418 patent records and 452 granted patents. As a result, large pharmaceutical companies are increasingly seeking to enter the CAR-T market by licensing patents from existing patent holders. Over the past decade, 91 CAR-T licensing deals have been valued at $6.3 billion, and this figure is expected to grow significantly over the next ten years.
While 2023 saw a resurgence in dealmaking, the CAR-T industry experienced a slowdown in mergers and acquisitions (M&A) in 2024, with only two deals completed. Although major M&A activity may not return in 2025, further deals are likely as large pharmaceutical companies look to deploy their cash reserves. Over the past decade, M&A deals have accounted for the largest share of CAR-T industry financing, totaling an impressive $97.4 billion.
In total, the CAR-T industry has raised more than $141.2 billion through various deal types, including IPOs, licensing deals, collaborations, and M&A transactions. It’s important to note that the values of 61 out of 91 licensing deals, 75 out of 110 collaboration deals, and 12 out of 29 M&A deals remain undisclosed. If we estimate the value of these undisclosed transactions, the overall total is likely to reach a staggering $281.7 billion.
Globally Approved CAR-T Therapies
Since 2017, 13 CAR-T cell therapies have reached commercialization across multiple healthcare markets. Seven therapies have been approved by the U.S. FDA, after which approvals for them were issued in other major healthcare markets as well. Beyond the U.S., four CAR-T therapies-Relma-cel, Fucaso, Yuanruida, and Zever-cel - have been approved by China’s National Medical Products Administration (NMPA). Additionally, two therapies, NexCAR19 and Qartemi, have received approval from India’s Central Drugs Standard Control Organisation (CDSCO).
All 13 approved CAR-T cell therapies are currently used exclusively to treat blood cancers, which account for less than 5% of cancer patients worldwide. Today, there are approximately 1,944 ongoing clinical trials focused on addressing both blood cancers and solid tumors. Of these, only 244 trials are targeting solid cancers. This swell of clinical trials has been driven by the remarkable 90% remission rate achieved by most of the approved CAR-T therapies.
CAR-T Market Overview
To track funding within this rapidly growing industry, the publisher has released this 220-page CAR-T market funding report. It summarizes all types of investments flowing into CAR-T companies worldwide, including financing rounds, IPOs, M&A transactions, co-development agreements, and strategic partnerships. Additionally, it profiles 78 leading competitors who have been involved with these CAR-T industry funding events.
This report reveals the following information for the CAR-T Cell Therapy Industry:
- Financing Rounds
- IPOs
- Asset Agreements
- Strategic Partnerships
- Co-Development Agreements
- M&A Transactions
- Companies Profiles for CAR-T Market Competitors
You can use it to:
- Quantify CAR-T industry investments
- Identify well-capitalized companies
- Scout potential partnerships and alliances
- Understand partnerships and co-development programs for CAR-T technologies
- Identify M&A activity within the CAR-T industry
To summarize, CAR-T companies - from emerging start-ups to billion-dollar enterprises - have completed hundreds of billions of dollars in financial transactions in recent years. These companies are rapidly expanding across global healthcare markets. This report delivers essential insights into the financial forces driving the industry, revealing where capital is flowing and how you can strategically position yourself to benefit from these trends.
Table of Contents
Companies Mentioned
- Bellicum Pharmaceuticals
- CRISPR Therapeutics
- Autolus
- Cellular Biomedicine Group
- Adicet Bio
- Autolus Limited
- Cellular Biomedicine Group
- Carina Biotech
- PeproMene Bio
- Precision BioSciences
- Cabaletta Bio
- Vor Biopharma
- Gracel Biotechnologies
- Mustang Bio
- Poseida Therapeutics
- BioNTech
- Adicet Bio
- Kyverna Therapeutics
- EXUMA Biotech
- IASO Biotherapeutics
- Legend Biotech
- JW Therapeutics
- Vor Pharma
- ImmPACT Bio
- Synthekine
- Gracell Biotechnologies
- CARsgen Therapeutics
- Umoja Biopharema
- Juventas Cell Therapy
- Celyad Oncology
- Artiva Biotherapeutics
- Caribou Biosciences
- Biosceptre
- Noile-Immune Biotech
- Arcellx
- Cellares Corporation
- Interius BioTherapeutics
- Synthekine
- Umoja Biopharma
- Wugen
- Mnemo Therapeutics
- AvenCell
- Currus Biologics
- Juventas Cell Therapy
- Carina Biotech
- IASO Biotherapeutics
- Cellular Biomedicines
- AffyImmune Therapeutics
- Leucid Bio
- Clade Therapeutics
- SOTIO Biotech
- EXUMA Biotech
- ImmPACT Bio
- Kyverna Therapeutics
- Ucello Therapeutics
- Mustang Bio
- Wugen
- Inceptor Bio
- Tessa Therapeutics
- Immuneel Therapeutics
- OriCell Therapeutics
- Carina Biotech
- Juventas Cell Therapy
- Arsenal Biosciences
- Synthekine
- IASO Biotherapeutics
- MPC Therapeutics
- OriCell Therapeutics
- Verismo Therapeutics
- Cargo Therapeutics
- OneChain Immunotherapeutics
- Caribou Biosciences
- Verismo Therapeutics
- Kyverna Therapeutics
- Gracell Biotechnologies
- Cellares
- Celyad Oncology
- Capstan Therapeutics
- Limula
- Cargo Therapeutics
- Leman Biotech
- Immuneel Therapeutics
- Dynamic Cell Therapies
- Arsenal Biosciences
- AvenCell Therapeutics
- March Biosciences
- A2 Biotherapeutics
- Umoja Biopharma
- Juno Therapeutics
- Cellular Biomedicine Group
- Xenetic Biosciences
- Cellular Biomedicine Group
- Autolus Therapeutics
- Allogene Therapeutics
- Precision BioSciences
- Atara Biotherapeutics
- Xenetic Biosciences
- Cabaletta Bio
- Atara Biotherapeutics
- Legend Biotech
- Mustang Bio
- JW Therapeutics
- Atara Biotherapeutics
- Gracell Biotechnologies
- Vor Biopharma
- Adicet Bio
- CARsgen Therapeutics
- Xenetic Biosciences
- Caribou Biosciences
- Celyad Oncology
- Adicet Bio
- Legend Biotech
- Kyverna Therapeutics
- Arcellx
- TC Biopharm
- Celularity
- TC BioPharm
- Precision Biosciences
- Legend Biotech
- TC Biopharm
- Vor Biopharma
- Precigen
- TC Biopharm
- Celularity
- Legend Biotech
- Coeptis Therapeutics
- Caribou Biosciences
- Cargo Therapeutics
- Kyverna Therapeutics
- Mustang Bio
Methodology
The content and statistics contained within the publisher's reports are compiled using a broad range of sources, as described below.
Input Sources
- Clinical Trial Databases (ClinicalTrials.gov, International Clinical Trials Registry Platform, European Union Clinical Trials Register, Chinese Clinical Trial Registry, Others)
- Scientific Publication Databases (PubMed, Highwire Press, Google Scholar)
- Patent Databases (United States Patent and Trade Office, World Intellectual Property Organization, Google Patent Search)
- Grant Funding Databases (RePORT Database, CIRM, MRC, Wellcome Trust - UK, Others)
- Product Launch Announcements (Trade Journals, Google News)
- Industry Events (Google News, Google Alerts, Press Releases)
- Company News (SEC Filings, Investor Publications, Historical Performance)
- Social Analytics (Google Adwords, Google Trends, Twitter, Topsy.com, Hashtagify.me, BuzzSumo.com)
- Interviews with Stem Cell Industry Leaders
Research & Analysis Methodologies
The publisher employs the following techniques for deriving its market research:
- Historical Databases: As the first and only market research firm to specialize in the stem cell industry, the publisher has 13+ years of historical data on each segment of the stem cell the industry. This provides an extremely rare and robust database for establishing market size determinations, as well as making future market predictions.
- Prolific Interviews with Industry Leaders: As the global leader in stem cell industry data, the publisher has interviewed hundreds of leaders from across the stem cell industry, including the CEO of FUJIFILM CDI, FUJIFILM Irvine Scientific, Pluristem Therapies, Celularity, and many others.
- Industry Relationships: The research team and its President/Founder, Cade Hildreth, Chair and present at a wide range of stem cell industry events, including Phacilitate's Advanced Therapies Week, World Stem Cell Summit (WSCS), Perinatal Stem Cell Society Congress, AABB's International Cord Blood Symposium (ICBS), and other events hosted within the U.S. and worldwide.
- Global Integrated Feedback: Because the publisher maintains the world's largest stem cell industry news site that is read by nearly a million unique readers per year and the company has large social media audiences (25.7K+ followers on Linked, 21.2K+ followers on Twitter, and 4.3K+ followers on Facebook), the publisher is able to publish content relevant to the industry and receive immediate feedback/input from a global community of readers. In short, the publisher's data is crowd-sourced from market participants worldwide, including those in diverse geographic regions.
- Preliminary Research: In addition to the interviews described above, the publisher conducts market surveys, executes social media polls, and aggregates market data from stem cell industry announcements, press releases, and corporate filings/presentations.
- Secondary Research: The publisher summarizes, collects and synthesizes existing market research that is relevant to the market area of interest.
- Future Projections: Using the resources described above, the publisher is uniquely positioned to make future projections about market size, market growth by segment, market trends, technology evolution, funding activities (financing rounds, M&A, and IPOs), and importantly, market leadership (market share by company).
LOADING...
